Organisation/Company: CNRS
Department: CNRS - INSERM - ENS
Research Field: Biological sciences » Biology, Medical sciences » Health sciences, Pharmacological sciences » Other
Researcher Profile: Recognised Researcher (R2)
Positions: Postdoc Positions
Country: France
Application Deadline: 31 Jan 2025 - 23:59 (Europe/Paris)
Type of Contract: Temporary
Job Status: Full-time
Offer Starting Date: 1 Nov 2024
Is the job funded through the EU Research Framework Programme? Horizon Europe - EIC
Reference Number: 101129622
Is the Job related to staff position within a Research Infrastructure? No
Offer Description Do you want to contribute to the development of a new therapeutic strategy to fight antimicrobial resistance? MaxImmun is a European project aiming to prevent and treat mucosal infections, and conflicts that may occur between a host and its microbiota, through the development of an innovative therapeutic strategy based on immunomodulatory molecules boosting the expression of antimicrobial peptides of the human immune system. This therapeutic strategy will be relevant in the fight against endemic infections in emerging countries and for infectious or inflammatory pathologies encountered in industrialized countries.
Missions To take part in the development of an innovative therapeutic strategy to fight antimicrobial resistance through the pharmaco-modulation of human genes encoding antimicrobial peptides.
To contribute to the understanding of the regulatory mechanisms of human innate immune genes encoding antimicrobial peptides.
Activities The dual objective of the project will be (i) to characterize the action mechanisms of immunomodulatory molecules identified by screening and capable of boosting expression of human genes encoding antimicrobial peptides, and (ii) to decipher a part of the fundamental regulatory mechanisms of these genes from the mucosal innate immunity. The candidate will study the activation and repression circuits as well as the impact of the immunomodulatory molecules on the regulation of the genes. Ultimately, the project will allow selecting among these molecules future drug candidates which could enter a R&D pipeline developed within the consortium, with the perspective of a phase I clinical trial.
Where to apply E-mail: ******
Requirements Research Field: Biological sciences » Biology
Education Level: PhD or equivalent
Skills/Qualifications Skills:
Cell biology
Molecular biology
Cell signalling
Genetic regulation
Epigenetic regulation
Knowledge:
Innate immunity
Antimicrobial peptides and inflammation
Genetic and epigenetic regulation
Conducting a research project
Communication principles and techniques
French and English languages: B2 to C1
Specific Requirements:
Genome and epigenome editing approaches
Gene silencing by siRNAs
Chromatin immuno-precipitation
RNA-seq and data analysis
Analysis of gene expression by quantitative real-time PCR (qPCR)
Analysis of the secretion of antimicrobial peptides by ELISA assays
Human cell culture
Fluent in French and English (written and spoken)
Organizational skills, practical and critical mind, and ability to anticipate
Proficient in Excel, Word, PowerPoint, and Prism software
Know-how:
Independent
Curious
Open-minded
Easy-going
Anticipative
Prioritization skills
Initiative
Synthetic
Responsive and dynamic
Rigorous and organized
Confidentiality
Languages:
FRENCH: Excellent
ENGLISH: Excellent
Research Field: Biological sciences » Biology
Years of Research Experience: 1 - 4
Additional Information Contract Period: 36 months
Proportion of work: Full time
Remuneration: Between 3,000€ and 4,700€ according to experience
Eligibility criteria:
Background: Immunology, Innate immunity, Inflammation, Antimicrobial peptides
Desired level of education: Niveau 8 - (PhD)
Selection process Selection based on application file (CV + motivation letter) and interview.
Additional comments The MaxImmun European project is based on a consortium made up of six partners (INSERM, CNRS, ENS in France; Helmholtz in Germany; Uppsala University in Sweden; ImmunRise Technologies French SME). The objective is to develop an innovative therapeutic strategy to fight antimicrobial resistance.
#J-18808-Ljbffr